AAN 2021 | Bone marrow-derived stem cells to treat stroke, MS and chronic TBI

Sean Savitz, MD, The University of Texas Health Science Center, Houston, TX, discusses the latest clinical trials assessing the use of stem cell-based therapy for the treatment of neurological disorders. Prof. Savitz highlights the randomized, placebo-controlled MASTERS trials (MASTERS, NCT01436487; MASTERS-2, NCT03545607) of the allogeneic bone marrow-derived adherent stem cell product, MultiStem, for stroke treatment and enhanced recovery. Interesting data has also been obtained in trials using marrow stromal cells to target disease progression in multiple sclerosis (MS), as well as improving impairment in patients with chronic traumatic brain injury (TBI). This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.